Oct 23 (Reuters) - Sumitovant Biopharma Ltd, along with parent Sumitomo Pharma Co Ltd, has entered into a deal to purchase all shares of Myovant Sciences not already owned by Sumitovant for $27 per share, the companies said in a statement on Sunday. (Reporting by Ann Maria Shibu in Bengaluru; Editing by Shailesh Kuber)
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
373 JPY | -6.75% | -9.02% | -19.96% |
May. 02 | Fed Outlook, Earnings Season Roil Asian Stock Markets | MT |
May. 02 | Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024 | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.96% | 969M | |
+26.08% | 662B | |
+21.85% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 290B | |
+13.68% | 234B | |
+3.65% | 198B | |
-11.12% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- 4506 Stock
- News Sumitomo Pharma Co., Ltd.
- Sumitovant Biopharma to buy Myovant for $27 per share